Myeloid sarcoma is an extramedullary tumor composed of immature myeloid cells that efface the underlying tissue architecture. It is usually associated with acute myelogenous leukemia, but can be associated with myeloproliferative neoplasms, myelodysplastic disorders, or myeloproliferative/ myelodysplastic syndromes. If it is unrecognized, appropriate chemotherapy may be delayed and survival jeopardized. We present a case of a myeloid sarcoma presenting in an otherwise asymptomatic patient who ultimately was found to have chronic myelogenous leukemia, presenting in blast crisis. We also review the distinct clinical and pathologic features of myeloid sarcoma, as well as treatment of the disease. P revious nomenclature for myeloid sarcoma included granulocytic sarcoma, myeloblastoma, extramedullary myeloid tumor, and chloroma. The term chloroma is derived from the Greek chloros, meaning green, as the tumor appears green when exposed to air (1) . Myeloid sarcoma is associated with a small percentage of acute myelogenous leukemia (AML) cases, approximately 3% to 5% (2). However, myeloid sarcomas can also arise in the setting of chronic myelogenous leukemia (CML) in blast crisis. The pathologic diagnosis of myeloid sarcoma can be challenging on hematoxylin and eosin sections alone. Immunohistochemical stains help to characterize the cell of origin and provide defi nitive diagnosis of myeloid sarcoma. Once diagnosed, myeloid sarcoma is treated according to the associated underlying disease state.
CASE PRESENTATION
A 35-year-old previously healthy man presented with right posterior shoulder pain. A fi rm, fi xed 2 cm soft tissue mass was palpated in the region of the right scapula. In addition, a nontender 4 cm axillary lymph node was palpated. Imaging with computed tomography of the chest revealed a single lytic lesion within the inferior angle of the right scapula. Th e diff erential diagnosis included metastatic disease, infection, and lymphoma. A core needle biopsy was performed of the right axillary node, and histologic evaluation revealed a monotonous population of medium-sized cells with vesicular chromatin and small nucleoli with a background of eosinophils and scattered megakaryocytes (Figure 1) . Th e immature mononuclear cells stained positive for progenitor markers (CD34 and CD117) and myeloperoxidase. Th e morphologic and immunophenotypic fi ndings supported the diagnosis of myeloid sarcoma.
Subsequently, a bone marrow aspirate and biopsy were performed. Review of the peripheral blood revealed moderate leukocytosis (18.3 k/μL) with an absolute neutrophilia, left shifted myeloid lineage, and rare (2%) circulating blasts. Th e bone marrow biopsy was 90% cellular with markedly increased reticulin fi brosis (grade 3 of 3). Immunohistochemical stains on the bone marrow biopsy showed 15% to 20% CD34-positive blasts ( Th e patient was treated with dasatinib 140 mg daily for 2.5 months and referred for allogeneic stem cell transplant. A repeat bone marrow was performed after 2 months of dasatinib treatment. Th e aspirate smear showed 2% blasts with a myeloid to erythroid precursor ratio of 1:1. Th e aspirate clot displayed 80% cellularity with trilineage maturation. Flow cytometry found no increase in myeloblasts. Th ere was no morphologic evidence of residual disease. However, molecular studies were positive for the t(9;22) BCR/ABL1 major (p210) fusion transcript in 1.04% IS by RT-PCR quantifi cation analysis. Fluorescence in situ hybridization was positive for the BCR/ ABL1 gene rearrangement in 4% of interphase cells identifi ed. Th ese fi ndings signifi ed a complete hematologic response and partial cytogenetic response at 2 months. Approximately 4 months after his diagnosis, the patient received an allogeneic matched unrelated donor transplant.
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DISCUSSION
In our patient, the initial presentation of a soft tissue myeloid sarcoma led to the diagnosis of an underlying CML in blast crisis. Although asymptomatic, the underlying reticulin fi brosis suggested the disease had been present in a chronic phase for some time. Th e diagnosis of CML in blast crisis may not have been made or may have been further delayed if not for the detection of the myeloid sarcoma in this otherwise asymptomatic patient.
Review of prior publications revealed a high misdiagnosis rate of myeloid sarcoma. It is most frequently misdiagnosed as non-Hodgkin lymphoma, but can also be mistaken for Ewing sarcoma/primitive neuroectodermal tumor and undiff erentiated carcinoma (3, 4) . When based solely on hematoxylin and eosin stain, the diagnosis is incorrect in approximately 50% of cases (5) . Furthermore, given the poor median survivals and options for long-term remission or cure in CML blast crisis, prompt and accurate diagnosis of this disease is imperative.
When considering the diagnosis of myeloid sarcoma, an appropriate panel of stains includes several immunohistochemical stains and special stains, specifi cally CD34, CD43, lysozyme, myeloperoxidase, CD68 (monocyte marker), CD163 (monocyte marker), and CD117 (3, 4, 6) . It can be helpful to include a CD3 and CD20 stain to exclude non-Hodgkin lymphoma. Th e most sensitive markers for myeloid sarcoma are CD43, lysozyme, myeloperoxidase, and CD68 (4). Myeloperoxidase is localized to the primary granules of myeloid cells and occurs early in diff erentiation, making it a helpful marker for identifying myeloid lineage. No single immunohistochemical stain can establish the diagnosis of myeloid sarcoma; rather, a combination of morphologic fi ndings and several immunohistochemical and special stains are required.
CML is a myeloproliferative disease characterized by the presence of the BCR/ABL1 fusion gene. Th e CML chronic phase classically presents with neutrophilic leukocytosis with an increased percentage of myelocytes, metamyelocytes, bands, and segmented neutrophils (7) . Th ere is also frequently an absolute basophilia in CML. Th e bone marrow is hypercellular with a dense layer of paratrabecular immature granulocytes and <5% blasts. Reticulin fi brosis can be identifi ed in 30% of cases in the initial marrow, which is associated with a worse prognosis (8) . CML blast phase can be diagnosed if the blast count is at least 20% of the white blood cells in the peripheral blood or in the nucleated cells in the bone marrow. It can also be diagnosed if an extramedullary blast proliferation is identifi ed (i.e., myeloid sarcoma). Prior studies have reported a range of 7% to 17% prevalence of extramedullary disease in patients with CML blast phase (9) (10) (11) . In most cases, the blast proliferation is of myeloid origin, and a minority of cases display a lymphoid proliferation (12) . Immunophenotypic analysis by fl ow cytometry and/or immunohistochemical stains can help diff erentiate the blast origin. Extramedullary blast proliferations are commonly identifi ed as myeloid sarcomas and most commonly present in lymph nodes, soft tissue, skin, and bone (3); however, they have been documented in many other organs.
Blast crisis remains a challenge in the management of CML. Th e introduction of BCR-ABL tyrosine kinase inhibitors has fundamentally changed the natural history, prognosis, and treatment of CML. Survival in chronic-phase CML is now estimated at a median of 25 to 30 years (13) . As such, progress to blast crisis has been reduced to approximately 1% per year compared to 20% per year in the pre-imatinib era (13, 14) . However, median survival after diagnosis of blast crisis currently ranges from 7 to 11 months compared with 3 to 4 months in the pre-imatinib era, which illustrates a less-than-desirable improvement (15) (16) (17) .
Once blast crisis has been diagnosed, management depends on previous therapy and type of leukemia (myeloid or lymphoid) (13, 15) . Best results are achieved for the few patients who return to chronic phase and are successfully transplanted (14) . Available choices for newly diagnosed, tyrosine kinase inhibitor-naïve patients include imatinib, dasatinib, or nilotinib (15) (16) (17) . Also, the recent approval of next-generation tyrosine kinase inhibitors like bosutinib and ponatinib provides clinicians multiple treatment options for patients with advanced-phase CML (18) . Appropriate patients should be referred early for allogeneic stem cell transplant. Even in the imatinib era, the best outcomes continue to be observed for patients who undergo allogeneic stem cell transplant. According to the German CML Study Group, the 3-year survival of 28 imatinib-pretreated patients transplanted in advanced phases (25 in blast crisis) was 59% (14, 17) . Current guidelines recommend considering allogeneic stem cell transplantation after a reasonable attempt has been made with a suitable tyrosine kinase inhibitor-selected therapy according to the mutation profi le (15) . If tyrosine kinase inhibitors alone are not suffi cient, acute leukemia-type induction therapy should be pursued. Th erefore, the best management of blast crisis is its prevention by an early and rigorous reduction to low levels or elimination of BCR-ABL (13) . The advent of tyrosine kinase inhibitor therapy has tremendously improved the clinical outlook for patients with CML. However, the number of eff ective treatment options is limited in advanced-phase (accelerated phase or blast crisis) CML, and treatment modalities eff ective in chronic-phase CML are not nearly as eff ective in advanced-phase CML (18) . Active clinical research of investigational agents and combination regimens is needed to expand treatment options available to patients such as the one presented here.
